产品
编 号：F180582
分子式：C16H16N6O
分子量：308.34
分子式：C16H16N6O
分子量：308.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1527475-61-1
产品详情
生物活性：
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo.
体内研究：
PFE-360 (4 mg/kg 和 7.5 mg/kg，口服，BID，10-12 周) 处理有效降低 LRRK2-pSer935/总 LRRK2 比率，无显著不良反应。Animal Model:Female Sprague Dawley rats (NTac:SD) weighed 225-250 g.
Dosage:4 mg/kg and 7.5 mg/kg (pharmacokinetics and pharmacodynamics).
Administration:Orally BID for 10-12 weeks.
Result:The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing.The terminal bodyweights exhibited no significant changes.
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo.
体内研究：
PFE-360 (4 mg/kg 和 7.5 mg/kg，口服，BID，10-12 周) 处理有效降低 LRRK2-pSer935/总 LRRK2 比率，无显著不良反应。Animal Model:Female Sprague Dawley rats (NTac:SD) weighed 225-250 g.
Dosage:4 mg/kg and 7.5 mg/kg (pharmacokinetics and pharmacodynamics).
Administration:Orally BID for 10-12 weeks.
Result:The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing.The terminal bodyweights exhibited no significant changes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备